Implications of Removing Rosiglitazone's Black Box Warning and Restricted Access Program on the Uptake of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors Among Patients with Type 2 Diabetes.

Hickson, Ryan P; Cole, Ashley L; Dusetzina, Stacie B

Hickson, Ryan P; Cole, Ashley L; Dusetzina, Stacie B.

Afiliación

Hickson RP; 1 Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, and Department of Epidemiology, UNC Gillings School of Global Public Health, University of North Carolina, Chapel Hill.
Cole AL; 2 Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, and Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill.
Dusetzina SB; 3 Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee.

J Manag Care Spec Pharm ; 25(1): 72-79, 2019 Jan.

Article en En | MEDLINE | ID: mdl-30589625

Asunto(s)

Diabetes Mellitus Tipo 2/tratamiento farmacológico; Inhibidores de la Dipeptidil-Peptidasa IV/uso terapéutico; Etiquetado de Medicamentos; Infarto del Miocardio/inducido químicamente; Pioglitazona/uso terapéutico; Rosiglitazona/uso terapéutico; Adulto; Humanos; Persona de Mediana Edad; Pioglitazona/efectos adversos; Estudios Retrospectivos; Rosiglitazona/efectos adversos; Adulto Joven

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Etiquetado de Medicamentos / Inhibidores de la Dipeptidil-Peptidasa IV / Rosiglitazona / Pioglitazona / Infarto del Miocardio Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adult / Humans / Middle aged Idioma: En Revista: J Manag Care Spec Pharm Año: 2019 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google